Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

MYSTERIOUS: 3 - You Need To See This

Analysts Continue To See Upside In Salesforce Post Q2 Beat Despite Challenging Macros

Salesforce, Inc (NYSE:CRM) clocked 22% revenue growth to $7.72 billion in Q2, beating consensus. The EPS of $1.19 topped the consensus. The board approved a buyback of up to $10 billion. The Q3 and FY guidance were below the consensus. Mizuho analyst Gregg Moskowitz reiterated a Buy and cut the price target from $245 to $235.…

Benzinga

Salesforce Faces Price Target Cuts On Guidance Cut, Shares Slide

Salesforce Inc (NYSE: CRM) reported upbeat results for its second quarter, but lowered its annual projections.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 19, 2022

Upgrades

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Benzinga's Top Ratings Upgrades, Downgrades For August 15, 2022

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2022

Benzinga

Looking At Microsoft's Recent Whale Trades

A whale with a lot of money to spend has taken a noticeably bullish stance on Microsoft. Looking at options history for Microsoft (NASDAQ:MSFT) we detected 40 strange trades.

Benzinga

Walmart To $142? Plus This Analyst Raises Price Target On McDonald's

Keybanc raised the price target for McDonald's Corporation (NYSE: MCD) from $285 to $290. However, Keybanc analyst Eric Gonzalez maintained the stock with an Overweight rating. McDonald's shares fell 0.3% to $256.23 in pre-market trading.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Benzinga's Top Ratings Upgrades, Downgrades For July 14, 2022

Upgrades

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 12, 2022

Upgrades

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 11, 2022

Upgrades

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 6, 2022

Upgrades

Benzinga

BMO Capital Maintains Outperform Rating for Micron Technology: Here's What You Need To Know

BMO Capital has decided to maintain its Outperform rating of Micron Technology (NASDAQ:MU) and lower its price target from $115.00 to $85.00. Shares of Micron Technology are trading up 2.62% over the last 24 hours, at $59.97 per share.

Benzinga

Read How Analysts Reacted To Darden Restaurants' Q4 Results

Wedbush analyst Nick Setyan lowered the price target on Darden Restaurants Inc (NYSE:DRI) to $122 (3% upside) from $140 and kept a Neutral rating on the shares. The analyst noted that FY23 guidance is predicated on normalization in inflation trends in the second half and has lowered his FY23 EPS estimate to $7.60 from $8.41…

Benzinga

BMO Capital Maintains Market Perform Rating for Century Aluminum: Here's What You Need To Know

BMO Capital has decided to maintain its Market Perform rating of Century Aluminum (NASDAQ:CENX) and lower its price target from $14.00 to $9.00. Shares of Century Aluminum are trading down 14.52% over the last 24 hours, at $7.30 per share.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

BMO Capital Maintains Market Perform Rating for Gartner: Here's What You Need To Know

BMO Capital has decided to maintain its Market Perform rating of Gartner (NYSE:IT) and lower its price target from $315.00 to $265.00. Shares of Gartner are trading up 1.71% over the last 24 hours, at $234.27 per share. A move to $265.00 would account for a 13.12% increase from the…

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 21, 2022

Upgrades

Benzinga

BMO Capital Sees Almost 300% Upside On Centessa Stock

BMO Capital has initiated coverage on Centessa Pharmaceuticals plc (NASDAQ:CNTA) with a price target of $19 (293% upside), and an Outperform rating. The analyst writes that ZF874 is a differentiated oral therapy as it addresses the root cause of AATD. Early ZF874 data (N=2) demonstrated therapeutic efficacy in patients, but liver toxicity was also flagged.…

Benzinga

BMO Initiates Coverage On This Gene Editing Spearhead

BMO Capital initiated coverage of Intellia Therapeutics Inc (NASDAQ:NTLA) with a Market Perform rating and a $54 target price. The analyst says Intellia's gene-editing platform could potentially deliver transformative therapies. But challenges around the lack of clarity around an IND approval in the U.S., ongoing CRISPR/Cas9 IP litigations with Editas Medicine Inc (NASDAQ:EDIT), and high patient…

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

BMO Capital Says Risk/Reward For This Gene Stock Assumes Clinical Success

BMO Capital initiated coverage on Beam Therapeutics Inc (NASDAQ:BEAM) with a Market Perform rating and a price target of 41. BMO writes that it appreciates the high potential of Beam's next-generation editing approach, but clinical validation is yet to be established. Preclinical base editing data point to a favorable benefit/risk profile. Also Read: Pfizer, Beam…

Benzinga

BMO Capital & Credit Suisse Slash United States Steel Price Target - Read Why

BMO Capital analyst David Gagliano lowered the price target on United States Steel Corp (NYSE:X) to $23 (an upside of 15.5%) from $30 while maintaining the Market Perform rating on the shares. X provided its 'mid-quarter' update yesterday and mentioned that it expects 2Q22 EBITDA of $1.6 billion, vs. BMO/FactSet consensus of $1.5 billion. Related: United…

Benzinga

BMO Capital Maintains Market Perform Rating for United States Steel: Here's What You Need To Know

BMO Capital has decided to maintain its Market Perform rating of United States Steel (NYSE:X) and lower its price target from $30.00 to $23.00. Shares of United States Steel are trading up 1.76% over the last 24 hours, at $19.93 per share.

Benzinga

'That Made Me Look Closer': Why This Adobe Investor Is Cautious Ahead Of Q2 Earnings

Adobe Inc (NASDAQ: ADBE) is set to announce its quarterly results after the bell Thursday, and one investor sees warning signs ahead of the report.

Benzinga

BMO Capital Maintains Outperform Rating for Adobe: Here's What You Need To Know

BMO Capital has decided to maintain its Outperform rating of Adobe (NASDAQ:ADBE) and lower its price target from $535.00 to $450.00. Shares of Adobe are trading up 0.36% over the last 24 hours, at $372.98 per share. A move to $450.00 would account for a 20.65% increase from the current…

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 13, 2022

Upgrades

Benzinga

10 Biggest Price Target Changes For Friday

BMO Capital cut Lululemon Athletica Inc. (NASDAQ: LULU) price target from $344 to $304. Lululemon shares fell 0.2% to $302.00 in pre-market trading.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.